Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

Table 1 Summary of completed and ongoing clinical trials of anti- human epidermal growth factor receptor 2 agents in metastatic colorectal cancer

Study	Phase	Treatment	Number of patients	Patient population	RR	mPFS	mOS
Rubinson[39]	I/II	Cetuximab + pertuzumab	7	Chemo- and cetuximab-refractory	14%	2.1 mo	3.7 mo
Sartore-Bianchi (HERACLES)[40]	II	Trastuzumab + lapatinib	27	Chemo- and cetuximab/panitumumab-refractory	30%	21 wk	46 wk
Hainsworth (MyPathway)[44]	II	Trastuzumab + pertuzumab	34	Chemo-refractory	35%	NR	NR
Siena (HERACLES-RESCUE)[42]	II	Trastuzumab-emtansine	Recruiting	Chemo- and cetuximab/panitumumab and trastuzumab plus lapatinib-refractory
NCT03457896	II	Neratinib + trastuzumab or cetuximab	Recruiting	Cetuximab and/or chemo-refractory
MOUNTAINEER[45]	II	Tucatinib + trastuzumab	Recruiting	Chemo- and bevacizumab-refractory

RR: Response rate; mPFS: Median progression-free survival; mOS; Median overall survival; Chemo: Chemotherapy; NR: Not reported.